Statement: Code of Ethical Practices
Ottawa, April 12, 2018 – The following statement can be attributed to Pamela Fralick, President, Innovative Medicines Canada.
“All members of Innovative Medicines Canada are bound by the association’s Code of Ethical Practices. Innovative Medicines Canada does not audit member companies to ensure compliance with the Code. Members are responsible for adhering to the Code. Stakeholders may also file complaints with Innovative Medicines Canada if they believe that a member company is breaching the Code.
Innovative Medicines Canada’s Code of Ethical Practices contains many provisions regarding payments to healthcare professionals (HCPs). Gifts or other financial inducements are prohibited. Canadian HCPs may be compensated, at fair market value, for performing services which are detailed in a legal agreement between the parties. This work might entail developing and presenting educational materials to a variety of audiences (e.g., patients, caregivers, peers), and/or consulting or advising on aspects of the company’s business. As with any professional providing services, it is fair and appropriate to remunerate healthcare professionals for their time and expertise.
Innovative Medicines Canada facilitated the June 2017 Voluntary Disclosure of Payments by providing interested member companies with a framework to publish aggregated sums of payments to Canadian HCPs and healthcare organizations in June 2017. Ten member companies voluntarily self-reported payments in June 2017.”